Immunocore's CEO on KIMMTRAK sales and expanding into PRAME, autoimmune and more

blonca9
Jan 8, 2024
1 min read

Bahija Jallal talks about the experience Immunocore has gained commercializing KIMMTRAK since its 2022 approval and into what areas she hopes to expand the company's development.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Immunocore's CEO on KIMMTRAK sales and expanding into PRAME, autoimmune and more

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight